Career progression is rarely linear, and there is no single path to leadership. In our latest blog, Sinéad McKeon discusses what drove her move from the lab bench to project management. She reflects on the capabilities...
Filter blogs
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Veeva R&D and Quality Summit 2024
A conference on research, development and quality shows that collaboration is crucial to advancing life sciences. Three ICON clinical data scientists share what they learned.
-
The rise and role of AI in medical imaging
Discover how AI is revolutionising medical imaging and clinical trials, enhancing efficiency, accuracy, and patient outcomes through innovative applications in oncology, cardiology and more.
-
Digital health : patient safety and the next frontier
Medical and wearable devices, remote in-vitro diagnostics and digital therapeutic products - the rapidly evolving world of digital health is bringing more and more devices into patients’ hands. But along with the benefits, there are safety considerations for people and data.
-
SDoH data analysis for proactive outcome improvement: A multilayered approach
Social determinants of health affect patients in widely variable ways, and proper, multi-layered analysis is required to gain actionable insight into patient healthcare consumption and behaviour to optimise brand strategy and deliver better solutions and services to patients.
-
How AI could transform literature surveillance for pharmacovigilance
In pharmacovigilance AI could be used to detect adverse events sooner, offering benefits for patients and researchers.
-
SDoH data for efficient, patient-centred clinical trials
The social determinants of health (SDoH) are a key component of understanding and delivering better outcomes for patients.
-
.png?crop=yes&w=210&h=209&itok=HFg-4Niz "Pharmaceutical data standards conference")
Insights from PHUSE US Connect 2024
ICON recently attended the PHUSE US Connect Conference, which took place from February 25th to 28th in Bethesda, Maryland, participating in exhibitions, unique presentations and interactive discussions on key topics. ICON’s experts shared their insights in multiple presentations within the statistical programming sphere.
-
How pharma can use social determinant of health to address health equity
The majority of our disease risk is social and environmental, not genetic, meaning the social determinants of health are a key piece of the puzzle. Effectively leveraging SDoH data can help close the gap in health equity and reveal new insights to guide pharma brand growth.
-
How data intelligence tools are enhancing signal detection methods
Advancements in intelligence tools such as ICON’s Signet help overcome challenges with data volume, complexity and completeness to accurately and rapidly detect safety signals to ensure patient safety throughout the drug’s lifecycle.
-
Digital therapeutics considerations for CNS
This blog explores DTx in CNS clinical trials: regulatory landscape, data management, endpoints, payer coverage, and future trends.
-
Keeping up to date with the latest regulatory developments for decentralised clinical trials
This blog examines the crucial topic of regulating the use of DCTs, exploring what’s in place now and what sponsors need to consider as these methods continue to gain traction.
-
Realising the benefits of bringing decentralised cardiovascular trials to patients
This blog reflects on the success of the first fully decentralised cardiovascular trial during the COVID-19 pandemic and highlights key elements for future trials.
-
Keep eCOA off the critical path of clinical trial startup
In today’s patient-driven and competitive drug development landscape, healthcare organizations cannot succeed without active patient insight through COAs.
-
Data capture: The benefits and evolution of eCOA
As the demand for improving patient safety in clinical trials continues to rise, so will the use of technology as a way to better capture data and enhance clinical outcome assessments (COAs).
-
Harnessing digital health to advance traumatic brain injury clinical trials
Advances in wearable technology have provided an effective tool to monitor outcomes and facilitate the delivery of interventions in patients across indications, especially those in need of rehabilitation interventions.
-
Dirty data: How to manage data from wearables in clinical trials
How to manage data from wearables in clinical trials — from overcoming regulatory issues to handling challenges associated with dirty data.
-
Mapping digital health transformation: from digital endpoints to device selection
At ICON, our framework maps the transition from device selection to digital endpoint validation, leading to a better data management and risk mitigation.
-
Wearables across phases: How to best incorporate digital endpoints at every stage of clinical research
Once implemented properly, digital endpoints have the potential to enhance any trial, whether observational or interventional, or early or late phase.
-
Remote management: the new normal in a post-COVID world
As procedures typically carried out on-site continue to be managed remotely, sponsors will need to implement a remote clinical trial management strategy to mitigate further roadblocks that may arise and keep clinical trials moving forward.
-
Best practices for designing digital endpoints for COVID-19 clinical trials amid uncertainty
Utilising data from sensors, wearables and other digital health technologies can provide critical information on COVID- 19 related symptoms and identify digital biomarkers in real- time.
